Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
BACKGROUND The volume of haploidentical hematopoietic stem cell transplant (haplo‐HSCT) has increased dramatically in recent years. However, the associated higher risk of delayed engraftment may increase patient transfusion requirements. STUDY DESIGN AND METHODS The post‐HSCT RBC and platelet transfusions of 195 haplo‐HSCT recipients were evaluated. Patient and transplant‐related factors potentially impacting the number of products transfused and time to transfusion independence were assessed. RESULTS Nearly all (98.4%) patients were transfused in the first 30 days, and 59.2% were transfused between days 31 and 100. Among the transfused patients, medians of 5 units (interquartile range [IQR] = 3‐8) of RBCs and 11 units (6‐20) platelets were given in the first 30 days, and medians of 3 units (IQR = 1‐7) of RBCs and 6 units (2‐18) of platelets were transfused between days 31 and 100. Median times for achieving RBC and platelet transfusion independence were 34 (95% CI: 28‐40) and 25 (95% CI: 23‐27) days, respectively. Multivariable analyses showed that RBC transfusions in the 10 days before HSCT were associated with significantly increased and sustained RBC and platelet transfusion requirements. Major ABO incompatibility led to increased RBC transfusions. Advanced disease was associated with increased transfusions during the first 30 days, whereas GVHD increased platelet transfusions between days 31 and 100. Effects of age, sex, CD34+ cell dose, stem cell source, and conditioning regimen were limited or insignificant. CONCLUSIONS This study for the first time provided quantitative transfusion data on a large cohort of haplo‐HSCT recipients and identified factors predictive of increased transfusions.